Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 8/20 | 0.41 |
| ▸ | CA1 | P00915 | 7/20 | 0.41 |
| ▸ | CA9 | Q16790 | 3/20 | 0.41 |
| ▸ | MGAM | O43451 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SI | P14410 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | CA4 | P22748 | 2/20 | 0.34 |
| ▸ | CA5A | P35218 | 2/20 | 0.34 |
| ▸ | CA7 | P43166 | 2/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.34 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.34 |
| ▸ | CA6 | P23280 | 1/20 | 0.34 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7153059 | 1.00 | CA2 (0.41) | CA2CA1CA9MGAMGAA | |
| SCHEMBL17368119 | 1.00 | CA2 (0.41) | CA2CA1CA9MGAMGAA | |
| SCHEMBL7123996 | 1.00 | CA2 (0.41) | CA2CA1CA9MGAMGAA | |
| SCHEMBL18660486 | 1.00 | CA2 (0.41) | CA2CA1CA9MGAMGAA | |
| SCHEMBL19129772 | 1.00 | CA2 (0.41) | CA2CA1CA9MGAMGAA | |
| SCHEMBL19129723 | 1.00 | CA2 (0.41) | CA2CA1CA9MGAMGAA | |
| SCHEMBL23288110 | 1.00 | CA2 (0.41) | CA2CA1CA9MGAMGAA | |
| SCHEMBL20056397 | 1.00 | CA2 (0.41) | CA2CA1CA9MGAMGAA | |
| SCHEMBL21938541 | 1.00 | CA2 (0.41) | CA2CA1CA9MGAMGAA | |
| SCHEMBL5365686 | 1.00 | CA2 (0.41) | CA2CA1CA9MGAMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10428104-B2 | Substituted nucleoside derivatives useful as anticancer agents | PFIZER INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-9089515-B2 | Long chain N-alkyl compounds and oxa-derivatives thereof | THOMAS JEFFERSON UNIVERSITY (US) | 2015-07-28 | — | — | US | disclosed |
| US-9089515-B2 | Long chain N-alkyl compounds and oxa-derivatives thereof | THOMAS JEFFERSON UNIVERSITY (US) | 2015-07-28 | — | — | US | disclosed |
| US-8389565-B2 | Antidiabetic agents; controlling carbohydrate metabolism | SIMON FRASER UNIVERSITY (CA) | 2013-03-05 | — | — | US | disclosed |
| US-8389565-B2 | Antidiabetic agents; controlling carbohydrate metabolism | SIMON FRASER UNIVERSITY (CA) | 2013-03-05 | — | — | US | disclosed |
| US-8389565-B2 | Antidiabetic agents; controlling carbohydrate metabolism | SIMON FRASER UNIVERSITY (CA) | 2013-03-05 | — | — | US | disclosed |
| US-20110184019-A1 | Long chain N-Alkyl compounds and oxa-derivatives thereof | THOMAS JEFFERSON UNIVERSITY | 2011-07-28 | — | — | US | disclosed |
| US-20110184019-A1 | Long chain N-Alkyl compounds and oxa-derivatives thereof | THOMAS JEFFERSON UNIVERSITY | 2011-07-28 | — | — | US | disclosed |
| US-7816560-B1 | Long chain n-alkyl compounds and oxa-derivatives thereof | THOMAS JEFFERSON UNIVERSITY (US) | 2010-10-19 | — | — | US | disclosed |
| US-7816560-B1 | Long chain n-alkyl compounds and oxa-derivatives thereof | THOMAS JEFFERSON UNIVERSITY (US) | 2010-10-19 | — | — | US | disclosed |
| WO-1995012219-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1995-05-04 | — | — | WO | disclosed |
| EP-0322395-B1 | HETEROCYCLIC COMPOUNDS FOR INHIBITING VIRUS | Monsanto Company (US) | 1993-03-24 | — | — | EP | disclosed |
| US-5089520-A | Administering 1,4-dideoxy-1,4-imino-L-arabinitol or 1,4-dideoxy-1,4-imino-D-ribitol; human immunodeficiency virus | MONSANTO COMPANY (US) | 1992-02-18 | — | — | US | disclosed |
| US-5043416-A | Method of inhibiting virus | MONSANTO COMPANY (US) | 1991-08-27 | — | — | US | disclosed |
| US-4999360-A | Treatment of AIDS, polyhydroxy piperidine derivatives | MONSANTO COMPANY (US) | 1991-03-12 | — | — | US | disclosed |
| US-4861892-A | Method for synthesis of deoxymannojirimycin | G. D. SEARLE & CO. (US) | 1989-08-29 | — | — | US | disclosed |
| EP-0328508-A2 | Method for synthesis of deoxymannojirimycin | The NutraSweet Company (US) | 1989-08-16 | — | — | EP | disclosed |
| EP-0322395-A1 | Heterocyclic compounds for inhibiting virus | Monsanto Company (US) | 1989-06-28 | — | — | EP | disclosed |
| EP-0000092-A1 | Method of preparing ascorbic acid and intermediates specially adapted for use therein | PFIZER INC. (US) | 1978-12-20 | — | — | EP | disclosed |
| US-4111958-A | Ascorbic acid synthesis | PFIZER INC. (US) | 1978-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428104-B2 | Substituted nucleoside derivatives useful as anticancer agents | TYMP, NME1, DPYD | CA2 4688/4885CA1 4100/4885CA9 2498/4885 |
| US-20110184019-A1 | Long chain N-Alkyl compounds and oxa-derivatives thereof | OXA1L, OTC, PAICS | CA2 4806/4885CA1 4480/4885CA9 4506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.